Počet záznamů: 1  

Structure-activity relationship and biochemical evaluation of novel fibroblast activation protein and prolyl endopeptidase inhibitors with α-ketoamide warheads

  1. 1.
    0544791 - ÚOCHB 2022 RIV FR eng J - Článek v odborném periodiku
    Šimková, Adéla - Ormsby, Tereza - Sidej, Natan - Poštová Slavětínská, Lenka - Brynda, Jiří - Beranová, Jana - Šácha, Pavel - Majer, Pavel - Konvalinka, Jan
    Structure-activity relationship and biochemical evaluation of novel fibroblast activation protein and prolyl endopeptidase inhibitors with α-ketoamide warheads.
    European Journal of Medicinal Chemistry. Roč. 224, Nov 15 (2021), č. článku 113717. ISSN 0223-5234. E-ISSN 1768-3254
    Grant CEP: GA ČR(CZ) GA19-10280S; GA MZd(CZ) NV15-31379A; GA MŠMT(CZ) EF16_019/0000729; GA MŠMT(CZ) LM2015064
    Institucionální podpora: RVO:61388963
    Klíčová slova: fibroblast activation protein * seprase * FAP inhibitor * serine protease inhibition * prolyl endopeptidase * α-Ketoamide inhibitor
    Obor OECD: Medicinal chemistry
    Impakt faktor: 7.088, rok: 2021
    Způsob publikování: Open access
    Web výsledku:
    https://doi.org/10.1016/j.ejmech.2021.113717
    DOI: https://doi.org/10.1016/j.ejmech.2021.113717

    Peptidomimetic inhibitors of fibroblast activation protein (FAP) are regarded as promising tools for tumor targeting in vivo. Even though several peptidomimetic compounds with nanomolar potency have been described, broad chemical space for further modification remained unexplored. Therefore, we set to analyze the structure-activity relationship (SAR) of pseudopeptide compound series with α-ketoamide warheads in order to explore the contributions of the P1′ and P2′ moieties to the inhibitory potency. A series of novel inhibitors bearing varied P1′ and/or P2’ moieties was synthesized by combining a Passerini reaction-Amine Deprotection-Acyl Migration (PADAM) approach with peptide coupling and subsequent oxidation. The resulting compounds inhibited FAP and the related prolyl endopeptidase (PREP) with potencies in the nanomolar to sub-nanomolar range. The most potent FAP inhibitor IOCB22-AP446 (6d, IC50 = 89 pM) had about 36-fold higher inhibition potency than the most potent inhibitor published to date. The compounds were selective over FAP's closest homolog DPP-IV, were stable in human and mouse plasma and in mouse microsomes, and displayed minimal cytotoxicity in tissue cultures.

    Trvalý link: http://hdl.handle.net/11104/0321598

     
     
Počet záznamů: 1  

  Tyto stránky využívají soubory cookies, které usnadňují jejich prohlížení. Další informace o tom jak používáme cookies.